The India Biologics Market Forecast projects exceptionally high growth, with the global market size (estimated at $30.81 Billion USD in 2024) expected to reach approximately $166.91 Billion by 2035. This explosive expansion translates to a high Compound Annual Growth Rate (CAGR) generally in the range of 16.6% during the forecast period (2025–2035). This strong trajectory is anchored by expanding healthcare access and significant government investment.

To ensure long-term visibility, there is little bit change in content from now. A core assumption underpinning the India Biologics Market Forecast is the sustained advancement in regulatory pathways, which are increasingly aligned with global standards, facilitating faster product approvals. The forecast anticipates accelerated demand for next-generation biologics such as Gene Therapies, which are projected to be the fastest-growing segment, albeit from a smaller current base. Crucially, the forecast highlights that the Biosimilars segment will continue to drive the bulk of market revenue, capitalizing on upcoming patent expirations of blockbuster biologics worldwide and India's unparalleled manufacturing capability. [India Biologics Market Forecast]